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The effects of phenobarbital on the histology of the liver and the brain and on selected biochemical 
parameters of the liver of wistar rats were studied.  Histological examination showed prominent 
lesions in the liver and brain of the tested groups of rats.  Biochemical analysis revealed significant 
(P < 0.05) increase in the activities of alkaline phosphatase, alanine transaminase and in the level of 
cholesterol, with increased drug dosage.  These correlated with the pathological changes observed 
in the liver and the brain of the wistar rats.  The effects of phenobarbital on the liver and brain cells 
were found to be dose-dependent.  Half the LD50 of the drug (8mg/160g) administered on the rats 
caused reasonable injuries to the tissues of the liver and the brain of the wistar rats.  
 




There has been a resurgence of clinical interest 
in the role of phenobarbital (PB) for treating 
childhood epilepsy in Western countries (Pal, 
2007).  In 1912, PB became one of the first 
agents used against epilepsy (Shorvon and 
Farmer, 1988), and is today the most widely used 
anti-epileptic drug (AED) in the world (Pal, 2007). 
In resource-poor countries, an anticonvulsant that 
controls seizures and prevents recurrence would 
be ideal (Kokwaro et al., 2003). Diazepam is 
useful in status epilepticus, but it does not offer 
prophylaxis following single-dose administration 
(Ogutu et al., 2002), whereas multiple doses can 
cause respiratory depression (Crawley et al., 
2000). Phenobarbital would be ideal for use in 
resource-poor countries, since it is cheap, readily 
available, fast-acting and can be administered 
i.m. at peripheral health facilities with few 
resources (Kokwaro et al., 2003).  In western 
countries, phenobarbital has been in and out of 
favour as an AED (Pal, 2007).  Although widely 
used as a prophylactic against febrile seizures in 
the 1960s and 1970s, concerns about its 
neurobehavioral adverse effect profile led to a 
decline in its use for all seizure disorders 
(Shorvon, 1986). 
The reasons for renewed interest in 
phenobarbital arise mainly from doubts about the 
safety of new licensed pharmaceuticals and 
public disquiet over the unsatisfactory regulatory 
framework for preclinical evaluation of new 
medicines, particularly for children (Pal, 2007). 
Cost of treatment may also be a consideration: 
carbamazipine costs around ten times, and 
lamotrigine almost forty times as much as the 
equivalent dose of phenobarbital (Pal, 2003). 
The effects of phenobarbital on liver 
physiology are typified by hepatic hypertrophy, 
hyper proliferation of the smooth endoplasmic 
reticulum, and induction or repression of 
numerous genes, especially the genes of 
cytochrome P450 enzymes (Garcia-Allan et al., 
2000).  Hepatic hypertrophy induced by 
phenobarbital is mediated by a moderate 
increase in hepatocyte DNA synthesis and 
dramatic enlargement of individual hepatocytes 
(Carthew et al., 1998). Hepatic enlargement 
subsides after phenobarbital withdrawal, and this 
decrease in liver size is mediated by hepatocyte 
apoptosis (Bursch et al., 1984).  Also, liver 
regeneration in response to partial hepatectomy 
is markedly diminished in phenobarbital–treated 
rat and mouse livers (Aletti et al., 1981).  
Phenobarbital is also the prototype of liver tumor 
promoters, dramatically increasing tumor 
numbers when chronically administered after 
initial genotoxic carcinogen treatment (Bell and 
Michalopoulos, 2006). 
However, phenobarbital is still being 
used as a sedative in cases of gastrointestinal 
and asthmatic functional disorders, as well as to 
antagonize the adverse central stimulant effects 
of some drugs such as ephedrine, 
dextroamphetamine or theophylline. It is also 
used in cases of withdrawal syndromes of 
hypnosedative agents (Lopez-Munoz et al. 2005).  
In the field of neurology, phenobarbital is still 
employed, not only in the treatment of certain 
types of epilepsy (partial and tonic-clonic 
generalized seizures), but also in the emergency 
treatment of some types of convulsions, such as 
those associated with tetanus, eclampsia, 
cerebral hemorrhage, status epilepticus, or 
different forms of poisoning (Lopez-Munoz et al., 
2005).  Phenobarbital is also capable of 
improving the hepatic transport of bilirubin in 
patients with hemolytic jaundice, so that it can be 
used in newborn babies to treat 
hyperbilirubinemia and kernicterus (Lopez-Munoz 
et al., 2005). 
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The present study is therefore aimed at 
determining the effects of phenobarbital on the 
liver and brain of rats, with a view to determining 
whether it can cause any histological alteration(s) 
in these organs.  The effects of phenobarbital 
dosage and duration of administration on 
selected biochemical parameters of the liver were 
also studied. 
 
Materials and Methods  
 
Drug administration: The LD5  of phenobarbital 
sodium (PHTNa) in rats is 100mg/kg (Ruch et al., 
2003).  Administration was intraperitoneally, the 
starting does being about one-third of the LD
0
50. 
The test groups (groups 1-4, below) received 
respectively, a corresponding increase in drug 
dose while the control group (5) received no 
administration of drug. Drug was administered 
daily for a period of 3 weeks (Table 1).  
 
Table 1: Dosage of phenobarbital sodium 
administration  
Groups  Dose mg/160g Drug in mg/kg 
body wt 
ml/l 
1  (6 rats) 5.0 31.25 0.25 
2  (6 rats) 6.0 37.50 0.30 
3  (6 rats) 7.0 43.75 0.35 
4  (6 rats) 8.0 50.00 0.40 
5 (6 rats) 0.0 - - 
  
Animal sacrifice: Ten rats, comprising of two 
rats from each group, were randomly selected 
and painlessly sacrificed at the end of every week 
of drug administration by placing them in a 
container having chloroform-soaked wool. Their 
post mortem was performed immediately and the 
organs for study resected and fixed promptly in 
10% formal saline. Subsequently they were 
histological processed, their sera were collected 
and analyzed biochemically at each sacrifice for 
alanine transaminase, alkaline phosphatase and 
cholesterol levels (Mayne, 1994).  
 
Tissue processing: The liver and brain excised 
from the dissected rats were cleared of the 
adhering connective tissue, fixed for 24 hours by 
immersion in equal parts of 10% formal buffered 
saline.  There after, fixe  tissues were 
dehydrated in ascending grades of ethanol, 
cleared in xylene and embedded in liquid paraffin 
wax.  The tissues were sectioned to a diameter of 
3-5 microns using the Heitz 150 rotary microtome 
(Cambridge model).  The se tions were then 
subjected to Erlich’s Haematoxylin and Eosin (H 
and E) staining technique as described by Baker 
and Silverton (1985). Sections were examined 
using swift binocular microscope with in-built 






Histopathology: On examination of the 
photomicrographs from the five different groups 
of experimental animals, the control showed 
normal architecture of the tissues under study.  
The other four groups presented different levels 
of distortion from the normal cell framework with 
the greatest level being observed in test group 4 
whose animals received the largest drug dose 










 Fig. 1: The photomicrograph of 
an apparently normal liver tissue 
of rat (x 200), showing normal 
hepatocytes (h); clear and normal 

















Fig. 2: The photomicrograph of liver 
tissue of rat (x200) administered with 
5mg/160g (phenobarbital/body weight), 
after 3 weeks of administration, showing 
normal hepatocytes (h); frank red blood 









Observations made from the liver 
microphotographs showed that progressive 
increase in period of administration of 
phenobarbital initiated necrosis in the liver of the 
rats (Fig. 2).  The degenerative processes 
intensified evidenced by a large increase in 
vacuolation, as the dosage of phenobarbital was 













 Fig. 3: Photomicrograph of the normal 
cerebellum of the control group of rats 
(x200), showing the normal distribution 
of glial cells: macrocytes (a) in brain 













































Figure 3 was obtained from the control group of 
the rats, and showed normal brain tissue 
architecture.  Figures 4-6 however, displayed 
neurons with pyknotic nuclei and necrotic cells.  
Here, brain cells were largely replaced by pink-
staining debris, with phagocytic cells (microcytes) 
engulfing degenerate materials.  Figure 6 
represents brain tissues of group 4 rats, which 
were administered with 8mg of the drug per 160g 
body weight.  They exhibit an extensive 
neurodegeneration with an onset of gliosis. 
 
Biochemical parameters: The activities of two 
liver enzymes, alanine transaminase and alkaline 
phosphatase, together with cholesterol level in 
the serum of rats were analyzed against drug 
dose and duration of administration.  The effect of 
the drug was observed to be significantly dose 
dependent (p < 0.05).  Using a one-way analysis 
of variance, the increase in biochemical 
parameters within the three weeks of drug 
administration was found to be significant (p < 
0.05). 
 
Table 2: Cholesterol levels during the period 
of drug administration  
Fig. 4:  Photomicrograph of brain tissue 
cerebellum of rats (x200) from test group 1, 
administered with 5mg/160g (phenobarbital 
/ body weight) for 3 weeks. Contracted 
microglial cells adjusting to the initial 
effects of phenobarbital; macrocytes (m). 










in wk 2 
(mmol/l) 
Cholesterol 
in wk 3 
(mmol/l) 
0.0(control) 2.8 3.0 3.0 
5.0 3.1 3.2 3.6 
6.0 3.5 3.9 4.1 
7.0 4.3 5.0 5.8 
8.0 6.1 7.0 7.6 
 
Table 3: Alanine transaminase (ALT) levels 
during the period of drug administration  
 













in wk 3 
(iu/l) 
0.0(control) 10 11 11 
5.0 12 12 13 
6.0 12 13 13 
7.0 13 12 13 
8.0 19 21 25 
Fig. 5: Photomicrograph of brain 
tissue cerebellum of rats (x200) from 
test group 2, administered with 6mg - 
7mg phenobarbital /160g body weight 
for 1 week. Here, there is a reduction 
in microglial cells (i); macrocytes (a) 
are fairly constant 
Table 4: Alkaline phosphatase (ALP) levels 
during the period drug administration  
 













in wk 3 
(iu/l) 
0.0(control) 33 34 33 
5.0 69 76 87 
6.0 73 78 82 
7.0 88 86 98 
8.0 90 95 109 
Tables 2, 3 and 4 show the changes in the levels 
of cholesterol, alanine transaminase and alkaline 
phosphatase respectively, with increase in 
phenobarbital dosage. Table 2 shows a 
progressive increase in cholesterol level with 
increase in the period of phenobarbital 
administration, for each test group. There was 
also an increase in cholesterol level with increase 
in phenobarbital concentration. Similarly, the 
levels of both alanine transaminase (table 3) and 
alkaline phosphatase (table 4) increased with 
increase in the period of phenobarbital 
administration, and with increase in phenobarbital 
concentration. 
Fig. 6: Photomicrograph of brain tissue 
cerebellum of rats (x200) from test group, 
administered with 8mg/160g (phenobarbital 
/ body weight) for 2 weeks.  Here, there are 
cloudy, crowded neuronal cells; there are 
large pink-stained glial cells. The onset of 
liquefaction is visible. 
Using a one-way analysis of variance 
(ANOVA), the level of significance (p<0.05) of 
these increases with increased administration of 
phenobarbital was determined (table 5). It was 
found that increase in the level of either 
cholesterol, alanine transaminase or alkaline 
phosphatase was significant (p<0.05). 




Table 5: One-way analysis of variance for the determination of the level of significance of increases 
in the biochemical parameters with dosage of phenobarbital 
Parameters  Sum of 
squares 
df Mean square F  P 
Between groups  29.600 4 
Within groups  2.773 10 
Cholesterol level 
(mmol/l) in weeks 








Between  groups 7566.933 4 
Within groups  482.667 10 
Alkaline 
phosphatase level 


















A rise in plasma activities of alanine 
transaminase has been shown to characterize 
liver-cell damage, while alkaline phosphatase 
activities are increased in cholestasis (Mayne, 
1994).  The results obtained from this study 
showed significant increases (P < 0.05) in the 
plasma activities of alkaline phosphatase and 
alanine transaminase. Plasma level of cholesterol 
also increased significantly (P < 0.05).  This 
showed that high doses of phenobarbital or 
discrete doses administered for long periods had 
adverse effects on the liver.  This finding is further 
supported by the histological results which 
showed the formation of cellular vacuoles on 
administration of very mild doses of 
phenobarbital. 
The histological results obtained from 
the brain tissue showed that phenobarbital 
causes damage to the brain.  Neurodegeneration 
increases as phenobarbital dosage are increased 
progressing ultimately to gliosis and then 
liquefaction. This is in support of the finding by 
Yazar et al., (2002) that phenobarbital increased 
the activities of marker enzymes in the brain and 
the liver of mice. It has also been shown that 
phenobarbital increased the level of serotonin in 
the forebrain and cerebellum of mice with a 
hereditary susceptibility to seizures (Matsumoto 
et al., 1983). Similarly, Lewin and Bleck (1997) 
found that phenobarbital inhibits seizures by 
decreasing the activities of neurons. These 
findings agree considerably with the histological 
results obtained in this study which showed 
features that can indeed impair transmission of 
impulses and hence the functional ability of the 
brain. 
From all indications however, 
phenobarbital will continue to be clinically 
relevant in the treatment of epilepsy and other 
types of convulsions owing to the fact that it is 
very cheap compared to other remedies.  It is 
therefore necessary to advice that the drug be 
taken only on the prescription and under the strict 




Aletti, M. G., Presta, M. and Ragnotti, G. (1981). 
Liver growth after partial hepatectomy: 
influence of Phenobarbital  
 
 
administration. Exp. Mol. Pathol., 34: 
216-225. 
Baker, F. J. and Silverton, R. E. (1985). 
Introduction to Medical Laboratory 
Technology, 17th ed., Butterworth-
Heinemann, Oxford. 
Bell, A. W. and Michalopoulos, G. K. (2006). 
Phenobarbital Regulates Nuclear 
Expression of HNF -4α in Mouse and 
Rat Hepatocytes Independent of CAR 
and PXR. Hepatology, 44: 186-194. 
Bursch, W., Lauer, B., Timmermann-Trosiener, I., 
Barthel, G., Schuppler, J. and Schulte – 
Hermann, R. (1984). Controlled Death 
(apoptosis) of normal and putative 
preneoplastic cells in rat liver following 
withdrawal of tumor promoters. 
Carcinogenesis, 5: 453-458. 
Carthew, P., Edwards, R.E and Nolan, B.M. 
(1998). The quantitative distinction of 
hyperplasia from hypertrophy in 
hepatomegaly induced in the rat liver by 
phenobarbital.  Toxicol. Sci.,  44: 46 - 
51. 
Crawley, J., Waruiru, C., Mithwani, S. (2000). 
Effect of Phenobarbital on seizure 
frequency and mortality in childhood 
cerebral malaria: a randomized, 
controlled intervention Study. Lancet, 
355: 701 – 706. 
Crawley, J., Smith, S., Kirkham, F., Muthinji, P., 
Waruiru, C., and Marsh, K.  (1996). 
Seizures and status epilepticus in 
childhood cerebral malaria. Q. J. Med., 
89: 591 - 597. 
Garcia-Allan, C., Lord, P. G., Loughlin, J. M., 
Orton, T. C and Sidaway, J. E. (2000). 
Identification of phenobarbitone-
modulated genes in mouse liver by 
differential display.  J. Biochem. Mol. 
Toxicol., 14: 65 - 72. 
Kokwaro, G. O., Ogutu, B. R., Muchohi, S. N., 
Otieno, G. O. and Newton, C. R. J. C. 
(2003). Pharmacokinetics and Clinical 
effect of Phenobarbital in children with 
severe falciparum malaria and 
convulsions. B., J. Clin. Pharmacol., 56 
(4): 453 - 457 
Lewin, E. and Bleck, V. (1997). Cyclic AMP 
accumulation in cerebral slices: Effects 
of carbamazepine, Phenobarbital and 
phenytoin. Epilepsia, 18 (2): 237 - 242. 
Effects of phenobarbital administration on organ histology and biochemical activities of rats 
  
450
Lopez – Munoz, F., Ucha-Udabe, R. and Alamo, 
C. (2005). The history of barbiturates a 
century after their clinical introduction. 
Neuropsychiatry. Dis. Treat., 1 (4): 329 - 
343. 
Matsumoto, T., Hiramatsu, M. and Mori, A. 
(1983). Effects of Phenobarbital on 
serotonin level in forebrain and 
cerebellum of mice with a hereditary 
susceptibility to seizures. Biochem., 11 
(9): 837. 
Mayne, P. D. (1994). Clinical Chemistry in 
diagnosis and treatment, 6th ed., Edward 
Arnold, London. 
Ogutu, B. R., Newton, C. R. J. C., and Crawley, J. 
(2002). Pharmacokinetics and 
anticonvulsant effects of diazepam in 
children with severe falciparum malaria 
and convulsions. Br. J. Clin. Pharmacol., 
53: 49 - 57. 
Pal, D. K. (2003). Epilepsy control in the 21st 
century: leave no child behind. 
Epilepsia, 44: 273 - 275. 
Pal, D. K. (2007), Phenobarbital for Childhood 
epilepsy: Systematic Review. Paediatr. 
Perinat. Drug Ther., 7(1): 31-42. 
Ruch, R. J. and Klaunig, J. E. (2003). Kinetics of 
Phenobarbital inhibition of intercellular 
communication in mouse hepatocytes. 
Cancer Res., 48 (90): 2579 - 2522. 
Shorvon, S. D. (1986) Drugs in developing 
countries B. M. J., 292: 1666 -1667. 
Shorvon, S. D and Farmer, P. J. (1988). Epilepsy 
in developing Countries: a Review of 
epidermiological, sociocultural and 
treatment aspects. Epilesia, 29: 36-54. 
Yazar, E. O., Demir, M. and Elmas (2002). 
Phenobarbital effects on brain and liver 
tissue enzyme activity in mice. Acta Vet. 
Born, 71: 309 - 312. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
